145 results about "Influenza virus vaccine" patented technology

The invention is directed to novel live attenuated influenza virus (LAIV) vaccines comprising one or more microRNA (miRNA) Response Element(s) (MRE) within an influenza virus genome. The MREs useful for the present invention can be derived from any miRNA which is highly expressed in influenza-targeted cells of an animal in need of vaccination but are not expressed or are expressed at very low levels in species (e.g., embryonated chicken eggs) or cell lines used for a large-scale vaccine production. This allows efficient vaccine production but renders the vaccine virus susceptible to attenuation in the influenza-targeted cells of vaccinated animals expressing a cognate miRNA.

The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease. In particular the invention relates to vaccine formulations comprising an oil-in-water emulsion adjuvant and optionally 3D-MPL, their use in medicine, in particular their use in augmenting immune responses to influenza antigens, and to methods of preparation, wherein the oil in water emulsion comprises a sterol, a metabolisable oil and an emulsifying agent. The present invention also provides for new prime-boost vaccination regimes for immunising humans against influenza disease, and in particular for ensuring and ameliorating the immunre response to the booster administration, in which a first influenza virus vaccine is administered in the presence of an adjuvant.

Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.

The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain. As the invention does not require detailed knowledge of an emerging strain, a vaccine can be provided further in advance to reduce the risk and potential effects of a human pandemic outbreak.

The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines.

The invention discloses a foot-and-mouth disease genetic engineering mixed epitope vaccine and a preparation method thereof. The vaccine consists of the following four parts: a serial B cell epitope recombinant protein BI consisting of main neutralizing epitops of O-type foot-and-mouth disease viruses in Cathay, Transasia and Mya 98 pedigrees with a gene sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, a T-cell epitope recombinant protein TI consisting of serial connection of universal T-cell epitope and a plurality of foot-and-mouth disease virus specific T-cell epitopes with a gene sequence of SEQ ID NO:3 and an amino acid sequence of SEQ ID NO:4, Toll-like receptor 3 agonist-polyinosinic acid-polycytidysic acid and / or Toll-like receptor7 / 8 agonist-R848 serving as immunopotentiator, and 201 oil adjuvant. When being used for immunizing a pig, the BI and TI mixed epitope vaccine prepared by utilizing the method can produce a protective immunization effect the same as or better than that of an inactivated influenza virus Vaccines, and has a cross protection effect to viruses of the three pedigrees, so that the vaccine is a novel immune-enhanced O-type foot-and-mouth genetic engineering mixed epitope vaccine.

The present invention provides compositions for use as vaccines against the influenza virus, and rapid methods of producing such compositions. The composition include i) at least one peptide derived from an influenza virus, wherein the peptide is fused to a capsid protein derived from a plant virus forming a recombinant capsid fusion peptide and ii) at least one isolated antigenic protein or protein fragment derived from a human or avian influenza virus. The isolated antigenic protein or protein fragment derived from the human or avian influenza virus can be conjugated to the surface of the recombinant capsid fusion peptide.

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and genes from vaccine seed virus isolates which include a HA gene segment with a HA2 sequence encoding a HA2 that confers enhanced growth in cells in culture, such as Vero cells.

The invention discloses a production method for vaccines of avian influenza virus and other influenza virus such as swine influenza, dog influenza and equine influenza, which comprises the following steps of: (1) transfer of culture and cultivation of vaccine-made cells; (2) reproduction of vaccine-made virus seeds; (3) microcarrier suspension culture of MDCK cells in a bioreactor; (4) reproduction of vaccine-made virus liquid; and (5) harvest of the virus liquid. The production method has the advantages of reducing the production cost greatly and improving the yield and quality of the vaccines obviously, along with short production period, no restriction to raw material supply, small occupied area, easy and quick expansion of production scale, light environmental pollution, easy processing, high automaticity, low employment and easy realization of balanced and stable quality.

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

The invention provides a vaccine against diseases caused by influenza virus infection and an immunization method. The vaccine contains peptides derived from the M2 and / or HA proteins of influenza virus coupled to carrier proteins.

The invention provides an influenza virus vaccine using nanometer emulsion as an adjuvant and a method for preparing the same. The influenza virus vaccine consists of the following components in percentage by mass: 1 to 30 percent of diluted influenza virus vaccine, 1 to 50 percent of oil phase, 20 to 70 percent of emulsifying agent and 20 to 70 percent of auxiliary emulsifying agent. In the influenza virus vaccine using the nanometer emulsion as the adjuvant, the adjuvant, namely the nanometer emulsion, has the advantages of little toxicity, mild properties, obvious solubility-enhancing effect on medicaments, good fluidity, extremely low irritation on bodies and the like, so that the immunization effect of the influenza virus vaccine is greatly improved; compared with the adjuvant-free influenza virus vaccine, the influenza virus vaccine of the invention has the advantages of small dosage and high bioavailability; compared with other influenza virus vaccines using the adjuvant, the influenza virus vaccine of the invention has the advantages of greatly improving bioavailability, lowering irritation, reducing adverse reactions, prolonging vaccine-releasing time, improving the targeting property of the vaccine, reducing an attrition rate and the like.

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

The invention provides a method for preparing a Vero cell influenza virus vaccine. Seasonal trivalent influenza vaccines and pandemic influenza storage vaccines with qualified quality can be prepared by improving a vaccine purification process, combining hydrophobic chromatography with ion exchange and auxiliarily adopting other purification methods.

The invention discloses a serum-free whole suspension cultured MDCK cell strain domesticated by a one-step adaptation method and application thereof to preparation of influenza virus vaccines, and belongs to the technical field of veterinary biology. Adherent cells are domesticated into a single dispersed whole suspension MDCK cell line named MDCK-S within two months by the one-step adaptation method, and the strain preservation number is CGMCC No. 12256. The invention further provides a method of culturing influenza viruses using the cell line. The method for producing the H1N1 and H3N2 subtype swine influenza viruses through MDCK cell suspension culture can replace traditional chicken embryo production to significantly reduce the production cost and improve downstream purification efficiency, and can rapidly and steadily increase the production scale.

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.

Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and / or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA.

The invention discloses a method for producing a vaccine for avian influenza viruses and other influenza viruses such as a swine influenza virus, a canine influenza virus and an equine influenza virus. The method comprises the following steps of: subculturing cells for preparing the vaccine; (2) reproducing cytotoxic varieties; (3) performing microcarrier suspension culture on darby canine kidney (MDCK) cells in a bioreactor; (4) reproducing venom for preparing the vaccine; and (5) harvesting virus liquid. The method has the advantages of great reduction in production cost, short production period, no restriction to raw material supply, small occupied area, easy and quick expansion in production scale, low and readily treated environmental pollution, high degree of automation, few labors, easy equilibrium and stabilization in quality and obvious improvement on the yield and the quality of the vaccines.

The invention discloses an influenza virus subunit vaccine and a preparation method thereof. The influenza virus subunit vaccine is formed by further purifying cracked viral proteins through a cracking agent and a new purification method; each agent of subunit vaccine comprises more than 80% of H1N1, H3N2 and B type influenza hemagglutinin, and does not comprise adjuvant, thiomersal or other corrosion removers. The invention further provides the preparation method of the influenza virus subunit vaccine. The preparation method of the influenza virus subunit vaccine comprises the following steps of virus inoculation, virus multiplication culture, allantonic fluid harvesting, clarification, inactivation, ultrafiltration and concentration, cracking and overspeed centrifugal purification, gel filtration chromatography purification, mixture, filtration sterilization, subpackage, packaging and the like. The influenza virus subunit vaccine can improve safety, eliminate untoward effects caused by adjuvant and eliminate the toxic and side effects caused by thiomersalate.

The invention relates to the preparation field of the avian influenza virus vaccine, and especially relates to a method for cultivating recombinant avian influenza subtype virus through full-suspension cell. The method comprises the following steps: inoculating the recombinant avian influenza subtype virus chick embryo virus into MDCK monolayer cell to acclimate and culture, inoculating the harvested culture, repeating the cultivating until the proliferation speed of the recombinant avian influenza subtype virus is stable, wherein the virus content is larger than or equal to 10<7.5>EID[50]; and then inoculating the suspension cell; acquiring virus liquid while cultivating until the cytopathy achieves 75% or above, namely obtaining the recombinant avian influenza subtype virus. The chick embryo virus is firstly inoculated into the MDCK monolayer cell to acclimate and cultivate, and then is inoculated to the suspension MDCK cell, thereby effectively increasing the performance stability of the suspension virus obtained through the production, wherein the obtained suspension virus HA is larger than or equal to 1 to 1024, each 0.1ml virus content is larger than or equal to 10<8.0>EID[50], and each 1ml virus content is larger than or equal to 10<8.0>TCID[50].

The invention relates to an acquisition method and adaptive sites of an influenza A virus vaccine mammalian cell adaptive strain. According to the invention, a conventional influenza A vaccine skeleton strain is subjected to continuous passage in mammalian cells so as to obtain the mammalian cell adaptive strain; four amino acid sites on the viral protein coded by a virogene in the adaptive strain undergo mutation, which contributes to adaptability to the skeleton strain. The adaptive strain does not has enhanced pathogenicity on living bodies like chick embryos and mice, but has substantially improved adaptability to mammalian cells.